PMDA drug package insert
デュロキセチンカプセル20mg「明治」
PMDA Prescription drug · Meiji Seika ファルマ株式会社 · package insert Jun 1, 2023
Key facts
| Brand names | デュロキセチンカプセル20mg「明治」, デュロキセチンカプセル30mg「明治」, デュロキセチンOD錠20mg「明治」, デュロキセチンOD錠30mg「明治」 |
|---|---|
| Nonproprietary names | デュロキセチン塩酸塩 |
| Companies | 製造販売元／Meiji Seika ファルマ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | セロトニン・ノルアドレナリン再取り込み阻害剤 |
| Therapeutic category codes | 871179, 87119 |
| YJ codes | 1179052M1162, 1179052M2169, 1179052F3034, 1179052F4030 |
| Approval numbers | 30300AMX00129000, 30300AMX00130000, 30300AMX00131000, 30300AMX00132000 |
| Package insert edition | 第3版 |
| Package insert date | Jun 1, 2023 |
| PMDA document key | 780009_1179052F3034_1 |
| PMDA company code | 780009 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: